Print
Email
Print Edition Stories
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: RI plans launch of cord blood center
Cambridge-based biotech startup Catabasis Pharmaceuticals Inc. has raised some $1 million in a financing round, according to official documents.
According to the company’s website, it’s working on a new class of drugs that treat inflammatory diseases. Catabasis’ platform relies on small molecules that target the pathways related to the inflammatory response. The body’s own bad regulation of the inflammatory pathway is present in a number of diseases, including inflammatory bowel disease, diabetes, psoriasis, rheumatoid arthritis, and multiple sclerosis. The Catabasis technology is meant to treat inflammation more safely and effectively than is currently possible. Catabasis also claims it has already demonstrated in vitro and in vivo proof of concept for its CAT1000 compounds.
Now, according to an amendment document filed with the U.S. Securities and Exchange Commission, Catabasis has raised $1.075 million of a $2 million debt round.
A request for comment to Catabasis had not been returned by time of publication. The SEC filing lists Jill Milne as an executive. Milne is listed as a founder of Catabasis on her LinkedIn profile, and was previously senior director of biology for Sirtris Pharmaceuticals Inc., which was bought in June of 2008 for $720 million in cash by GlaxoSmithKline PLC.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
